 |
[Apha Biz=(Chicago) Reporter Paul Lee] Medytox (CEO Chung Hyun-ho), a global biopharmaceutical company, made an announcement on the 4th that it recently received approval to resume sales of botulinum toxin (export name Neuronox) from the Thai Food and Drug Administration (TFDA) and started exporting them in earnest.
The Thai Food and Drug Administration (TFDA) stopped selling Medytoxin in Thailand in 2020, citing the domestic administrative disposition of Medytox, but recently lifted the measure.
Meditoxin, which has surpassed 10 billion won in annual sales and established itself as Thailand's No. 1 toxin product, will be released again in the Thai market.
MedyCeles, a local joint venture established by Medytox and Thai beauty company Celeste, has signaled a recapture of the market through massive marketing.
MedyCeles is a joint venture established in March 2017 by Medytox with a beauty distributor to enter Thailand, Southeast Asia's largest skin beauty market in 2008.
Medy toxin has become the No. 1 toxin agent in Thailand, and the hyaluronic acid filler neuramis, which entered the Thai market in 2018, was able to grow into a unique product with more than 60% of the Thai market thanks to MedyCeles's strong sales power and supply chain.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
